Navigation Links
PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million
Date:3/11/2013

is certain amounts based on net sales of Lucentis, made by Novartis, during calendar year 2011 and beyond. The amount paid is less than we receive in royalties on such sales.

Reported worldwide sales for Avastin sales increased 10 percent in the fourth quarter of 2012 when compared to the same period in 2011.  Ex-U.S. manufactured and sold Avastin sales represented 50 percent of total Avastin sales in the fourth quarter of 2012 as compared with 27 percent in the fourth quarter of 2011.

Reported worldwide sales for Herceptin increased 11 percent in the fourth quarter of 2012 when compared to the same period in 2011. Ex-U.S. manufactured and sold Herceptin sales represented 41 percent of total Herceptin sales in the fourth quarter of 2012 as compared with 35 percent in the fourth quarter of 2011.

Reported worldwide sales for Lucentis increased 12 percent in the fourth quarter of 2012 when compared to the same period in 2011. All sales of Lucentis were from inventory produced in the United States.

Reported worldwide sales for Tysabri increased 16 percent for the fourth quarter of 2012 compared to the same period in 2011. Tysabri royalties are determined at a flat rate as a percentage of sales regardless of location of manufacture or sale.

The sales information presented above is based on information provided by PDL's licensees in their quarterly reports to the Company as well as from public disclosures made by PDL's licensees.

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new income generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioP
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PDL BioPharma to Hold Annual Meeting of Stockholders on May 21, 2013
2. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
3. PDL BioPharma Announces Fourth Quarter and Full Year 2012 Financial Results
4. BiOptix to highlight new carbonic anhydrase data at IBCs Biopharmaceutical Development & Production Week
5. Array BioPharma To Present At The Cowen Annual Health Care Conference
6. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
7. Promise and Problems Signal Mixed Year Ahead for Biopharmaceutical Industry, Says Pharmaceutical Executive Magazine
8. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
9. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
10. Matinas BioPharma to Present at the NYC Medical Technology Forum on February 5, 2013
11. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... June 30, 2014 results on Thursday, July 31, 2014, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/10/2014)... WEST JORDAN, Utah , July 10, 2014 /PRNewswire/ ... imaging solutions, and MiE America , Inc., a ... systems, have entered into a long-term agreement naming BC ... in the US. MiE and BC ... a strategic agreement to establish BC Technical as the ...
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... I Results Offer Hope of First Highly Effective Drug in ... June 1 Roche announced today results from a Phase ... promising treatment for patients with advanced melanoma whose cancer harbours ... PLX4032 lived for a median of at least six months ...
... Eli Lilly and Company announced today that Phase ... (gemcitabine HCl for injection) to the current standard of ... at three years for women with locally advanced cervical ... commonly diagnosed women,s cancer, and the second most common ...
Cached Medicine Technology:Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer 2Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer 3Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer 4Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer 5Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 2Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 3Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 4Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 5Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 6
(Date:7/12/2014)... 2014 For those who are unfamiliar with ... absorb the nutrients in food. The enzymes literally break up ... enough to be absorbed by human bodies. According Dr. Henry ... enzymes in regular food is the cause of many gastrointestinal ... started by Michelle DelPresto, a mother of 3 who is ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 “Critical ... - New and Late-Stage Four-Factor PCCs and Recombinant ... of the critical care market in the US, ... The report provides an estimation of market size ... It covers critical care indications that are being ...
(Date:7/12/2014)... York, NY (PRWEB) July 12, 2014 As ... (the National Institute of Standards and Technology), the June 25th, ... the electronic discovery world. It was also ... finally in, depending on whether it was seen from an ... But this much is fact, there is now precedent which ...
(Date:7/12/2014)... July 12, 2014 Dubai is buzzing ... legend is heading to the UAE. The National ... will be in the UAE from 28-31 October to ... support of diabetes awareness. The event is being organized ... and event management company based in Dubai. The announcement ...
(Date:7/12/2014)... 2014 Praeclarus Press is ... a valuable new resource for women in need of ... women work away from their children. Today’s mothers receive ... of breastfeeding, but often feel unsupported when it comes ... With its evidence-based insights, and written by Nancy Mohrbacher, ...
Breaking Medicine News(10 mins):Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2
... the same doctor during their first six months of ... screenings -- for lead poisoning, anemia and tuberculosis -- ... repeatedly by the same physician, often referred to as ... the children they studied. , Researchers from The Children,s ...
... Corporation of,North America, its U.S. subsidiary, MGI PHARMA, ... U.S. Food and Drug Administration,(FDA) has approved Aloxi(R) ... and vomiting (PONV) for up to 24 hours,following ... demonstrated., Aloxi, available in the United States ...
... the cause of a Hutchinson-Gilford Progeria Syndrome (HGPS), a ... to researchers at the National Cancer Institute (NCI), part ... findings, the first to indicate a biological basis for ... may also provide new insights into the biological mechanisms ...
... WATERBURY, Conn., March 2 Therap Services announces the,release ... and reporting applications. Therap version 7.2 will feature,new forms ... the Health,Tracking module and the Emergency Medical/Behavior Intervention Strategies,(EMBIS) ... in version 7.2 include: -- Behavior Plan and ...
... mirrors growth of disease, study says , , FRIDAY, Feb. ... between rising rates of carbohydrate intake and obesity and ... United States, a new study says. , Researchers noted ... 1973 to 2.1 million in 2001, which closely mirrors ...
... treatment and alcohol, drug use , , SATURDAY, March 1 ... for attention deficit-hyperactivity disorder (ADHD) might have one less thing ... kids are no more likely than their peers to abuse ... which was funded by the National Institutes of Health, is ...
Cached Medicine News:Health News:In early childhood, continuous care by 1 doctor improves delivery of health screenings 2Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 2Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 3Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 4Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 5Health News:Adult stem cell changes underlie rare genetic disease associated with accelerated aging 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 3Health News:ADHD Drugs Won't Raise Risk of Substance Abuse 2Health News:ADHD Drugs Won't Raise Risk of Substance Abuse 3
... The word cohesive is a new term being used ... to the more liquid fill that may have been ... is not new science, this is not new technology ... today to describe the sticking together nature of the ...
Nasal Implants are used to augment the shape or reshaping of the nose....
Inquire...
Inquire...
Medicine Products: